Form 8-K - Current report:
SEC Accession No. 0001213900-25-029407
Filing Date
2025-04-07
Accepted
2025-04-07 16:05:08
Documents
15
Period of Report
2025-04-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0237404-8k_immucell.htm   iXBRL 8-K 28950
2 INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND TIMOTHY C. FIORI DATED ea023740401ex10-1_immucell.htm EX-10.1 28124
3 PRESS RELEASE OF THE COMPANY DATED APRIL 7, 2025 ea023740401ex99-1_immucell.htm EX-99.1 9729
  Complete submission text file 0001213900-25-029407.txt   251310

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20250404.xsd EX-101.SCH 3014
5 XBRL LABEL FILE iccc-20250404_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE iccc-20250404_pre.xml EX-101.PRE 22358
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0237404-8k_immucell_htm.xml XML 3558
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 25818123
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)